Spirit Scientific Biotech: Innovating regenerative medicine by turning biomaterials into pharmaceuticals

 

Spirit Scientific Biotech is participating in the BIO Asia-Taiwan exhibition for the first time.
The well-known media outlet conducted a interview video with us.

Steven D. Lin, co-founder and chairman of Spirit Scientific Biotech, made his first appearance at BIO Asia-Taiwan, sharing the company’s innovative plans in the field of regenerative medicine.
Spirit Scientific Biotech focuses on the pharmaceutical and standardization of biomaterials.
Their core technology, BMLT, can significantly improve the stability and shelf life of biomaterials.
Their first product, Platelet Lyphoilized Treatment (PLT), is currently the safest and most complete pharmaceutical solution for platelet therapy, transforming platelet therapy into quantifiable and precise medicine.
Steven D. Lin stated that Spirit Scientific Biotech hopes to establish collaborations with domestic and international experts and medical centers to jointly promote the development of precision medicine and regenerative medicine.

Source: https://news.gbimonthly.com/tw/celebrity/show.php?num=79941

 

其他推薦文章

Articles
2025.12.02

Spirit Scientific passes Japan PMDA audit for cell processing facilities, showcasing biofoundry™ strength

2025.11.21

Spirit Scientific BioTech Wins Ministry of Economic Affairs'”Startup Award,” Innovative Operating Strategy Recognized

2025.10.28

Spirit Scientific gains recognition with double bronze for 2 patents at Innotech Expo, highlighting solutions for PRP limitations at Taiwanese Orthopaedic Association

2025.08.27

Spirit Scientific Biotech: Innovating regenerative medicine by turning biomaterials into pharmaceuticals

2025.08.06

Vice President acknowledge Golden Ship Award winners as Taiwan’s pride, showcase Taiwan’s strength to the world.

2025.07.31

Spirit Scientific biotech featured in famous media, Global Bio & Investment, Vol. 128

Scroll to Top